is reacted with carbonyldiimidazole to form an activated imidazoyl carbonate of the formula:

$$CH_2=CR_5-C(=O)-O-CH_2-CHR_6-(O-CH_2-CHR_6-)_n-O-C(=O)+Im$$

where R₅ and R₆, which may be the same or different, are each selected from H and CH₃; and n is from 0 to 49, and the activated inidazoyl carbonate is coupled with heparin at a basic pH.



device. ---

- 45. A coating material comprising a copolymer according to claim 22 or claim 23.
- 46. A coating material according to claim 45 adapted for use on a surface of a medical

REMARKS

The specification has been amended to correct a typographical error in formula 3, page 7. Support for the correct terminology for the formula can be found at least in original claim 8 and in the description of formula 3, as it appears immediately after the formula on page 7 of the specification.

An abstract of the disclosure has been enclosed herewith on a separate sheet as provided in 37 CFR §1.72(b). It is respectfully requested that such abstract be entered into the case.

Claims 1 - 21 have been cancelled without prejudice. New claims 22 - 46 have been added. The new claims find support in the cancelled claims and in the specification and have been redrafted to reduce the number of multiple dependent claims and to more clearly describe the claimed invention. No new matter has been added.

Request for Examination:

It is believed that this application is now in condition for examination and allowance and such actions are respectfully requested. If the Examiner finds, for any reason, one or all of the claims not to be allowable, it is requested that a telephone call be made to the undersigned at the number given below prior to the issuance of any final rejection so that any remaining issues can be resolved.

Respectfully submitted,

Charles E. Dunlap Reg. No. 35,124

Howell & Haferkamp, L.C.

7733 Forsyth Boulevard, Suite 1400

St. Louis, Missouri 63105

(314) 727-5188